Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX73086 in advanced solid tumors and TGCT
NCT02673736Phase 1Terminated
- Sponsor
- Plexxikon Inc.
- Start
- Feb 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLX73086 in solid tumor and tenosynovial giant cell tumor (TGCT), sponsored by Plexxikon Inc. Primary endpoints: Adverse Events and Serious Adverse Events at 1 year, Area Under the Concentration-Time Curve at 1 year and 3 more. Started Feb 2016; status: terminated.
02
Drugs
PLX73086
03
Conditions
solid tumortenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT02673736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673736.